Combining a first-in-class SLAMF7 antibody with SIRPα blockade for anti-tumor immunity

Cancer cells often overexpress CD47, which triggers the macrophage receptor SIRPα to elude anti-tumor immunity. We found that CD47 also suppresses phagocytosis by masking a pro-phagocytic ligand, SLAMF7, on tumor cells. We generated a first-in-class SLAMF7 antibody, which dissociated the CD47–SLAMF7...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature immunology 2023-12, Vol.24 (12), p.1978-1979
Format:	Artikel
Sprache:	eng
Schlagworte:	631/250/251 631/67/1059/2325 Biomedical and Life Sciences Biomedicine Cancer therapies Clinical trials Collaboration Immunity Immunology Immunotherapy Infectious Diseases Ligands Lymphoma Macrophages Mass spectrometry Monoclonal antibodies Phagocytes Phagocytosis Proteins Research Briefing Scientific imaging Toxicity Tumor cells Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Cancer cells often overexpress CD47, which triggers the macrophage receptor SIRPα to elude anti-tumor immunity. We found that CD47 also suppresses phagocytosis by masking a pro-phagocytic ligand, SLAMF7, on tumor cells. We generated a first-in-class SLAMF7 antibody, which dissociated the CD47–SLAMF7 cis interaction, enabling anti-tumor immunity during SIRPα blockade.
ISSN:	1529-2908 1529-2916
DOI:	10.1038/s41590-023-01673-0